Zanubrutinib's new tablet formulation is approved for all five indications, reinforcing its market leadership among BTK inhibitors. The 160 mg tablet simplifies dosing, reducing the daily intake from ...
MISSISSAUGA, ON, June 9, 2026 /CNW/ - Novo Nordisk today announced the Canadian availability of an updated formulation of Rybelsus® (semaglutide tablets), a prescription medicine used by adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results